Enorama Pharma: PRESS RELEASE FROM THE EXTRAORDINARY GENERAL MEETING, AND FIRST CONTROL MEETING, IN ENORAMA PHARMA AB (PUBL)

Enorama Pharma's extraordinary general meeting on 7 April 2026 resolved the company will continue operations and not enter liquidation. The board is pursuing a capital injection and other capital-raising measures from existing (and potentially new) investors, leaving the company dependent on successful funding and maintaining execution and liquidity risk.

Analysis

Avoiding liquidation is the start, not the finish — the immediate question is funding structure. Expect a directed rights issue, convertible instrument, or a minority private placement that materially dilutes current equity while preserving optionality for an anchor investor; timeline for binding terms is likely 2–12 weeks.

Second-order winners are cash-rich regional consolidators and mid-cap pharma buyers that can pick up specific assets with limited bidding (they pay control premiums well below global M&A norms); suppliers and CROs who negotiate debtor-in-possession style terms can recoup a disproportionate share of value compared with equity holders. Conversely, holders of small-cap biotech beta face renewed issuance pressure that historically depresses the cohort by 10–30% over the subsequent 3–9 months as deal arbitrage plays out.

Key catalysts to watch: announcement of financing instrument (rights vs private placement), identity of anchor investor, expiry of any standstill agreements, and whether convertible terms include anti-dilution — each will swing valuation materially within days of release. Tail risk remains binary — failure to secure credible capital triggers liquidation and near-total equity wipeout; successful structured financing that preserves IP can produce 2–5x recovery for new money within 12–24 months if partnered or sold.

Key Decisions for Investors

• Pair trade (3–9 months): Short XBI (SPDR S&P Biotech ETF) and go long SOBI.ST (Swedish Orphan Biovitrum). Thesis: small-cap biotech cohort to underperform on issuance pressure while regional consolidator (SOBI) benefits from acquisitive optionality. Risk/reward: asymmetric — downside if broad biotech M&A heats up; target 20–40% relative return, stop-loss at 10% adverse divergence.
• Event-driven (weeks–3 months): Buy OTM put spread on XBI (e.g., buy 1m 95/85 put spread) to hedge acute issuance risk around Swedish microcap financings. Cost-effective downside protection if multiple rights issues hit market simultaneously; limited premium, uncapped payoff to 10% index decline.
• Opportunistic (6–24 months): Allocate small, high-conviction capital to newly issued equity or convertibles of post-financing mid-stage Swedish biotechs (entry after prospectus). Aim for 2–5x IRR if instruments include warrants/convertible features; primary risk is pipeline failure or unfavorable partner terms — size position <=1% NAV.
• Risk management: Maintain 25–50% hedge on any Scandinavian biotech exposure via IBB (iShares Nasdaq Biotechnology ETF) or XBI puts and reduce gross long exposure until financing terms are disclosed. This limits idiosyncratic wipeout risk from failed recapitalizations.